Ghada Algwaiz1, Ahmed Ali Badran2,3, Mahmoud A Elshenawy2,4, Taher Al-Tweigeri2. 1. Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 2. Department of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 3. Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 4. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt.
Abstract
BACKGROUND: Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have been a significant breakthrough in the management of hormone receptor-positive, HER2-negative metastatic breast cancer based on the results of several large phase III randomized trials. The most common reported toxicity is myelosuppression due to disease such as leukopenia, neutropenia, and thrombocytopenia. Other toxicities associated with CDK 4/6 inhibitors include mucositis, fatigue, gastrointestinal side effects, hepatic toxicities, and QTc prolongation. Despite a good toxicity profile in pivotal studies, the increased rates of use in clinical practice may show less prevalent but lethal toxicity such as lung injury. CASE PRESENTATION: Here, we describe a female patient with metastatic hormone receptor-positive/human epidermal growth factor 2-negative breast cancer who developed lung toxicity while on ribociclib. DISCUSSION: Lung injury is a possible side effect of CDK 4/6 inhibitors and there is an increasing need to understand the management of this side effect.
BACKGROUND: Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have been a significant breakthrough in the management of hormone receptor-positive, HER2-negative metastatic breast cancer based on the results of several large phase III randomized trials. The most common reported toxicity is myelosuppression due to disease such as leukopenia, neutropenia, and thrombocytopenia. Other toxicities associated with CDK 4/6 inhibitors include mucositis, fatigue, gastrointestinal side effects, hepatic toxicities, and QTc prolongation. Despite a good toxicity profile in pivotal studies, the increased rates of use in clinical practice may show less prevalent but lethal toxicity such as lung injury. CASE PRESENTATION: Here, we describe a female patient with metastatic hormone receptor-positive/human epidermal growth factor 2-negative breast cancer who developed lung toxicity while on ribociclib. DISCUSSION: Lung injury is a possible side effect of CDK 4/6 inhibitors and there is an increasing need to understand the management of this side effect.
Authors: Jennifer J Gao; Joyce Cheng; Erik Bloomquist; Jacquelyn Sanchez; Suparna B Wedam; Harpreet Singh; Laleh Amiri-Kordestani; Amna Ibrahim; Rajeshwari Sridhara; Kirsten B Goldberg; Marc R Theoret; Paul G Kluetz; Gideon M Blumenthal; Richard Pazdur; Julia A Beaver; Tatiana M Prowell Journal: Lancet Oncol Date: 2019-12-16 Impact factor: 41.316
Authors: Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia V Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Manu Sondhi; Yingbo Wang; Arunava Chakravartty; Karen Rodriguez-Lorenc; Tetiana Taran; Guy Jerusalem Journal: N Engl J Med Date: 2019-12-11 Impact factor: 91.245
Authors: G N Hortobagyi; S M Stemmer; H A Burris; Y S Yap; G S Sonke; S Paluch-Shimon; M Campone; K Petrakova; K L Blackwell; E P Winer; W Janni; S Verma; P Conte; C L Arteaga; D A Cameron; S Mondal; F Su; M Miller; M Elmeliegy; C Germa; J O'Shaughnessy Journal: Ann Oncol Date: 2018-07-01 Impact factor: 32.976
Authors: George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac Journal: JAMA Oncol Date: 2020-01-01 Impact factor: 31.777